LiberiaTuberculosis profile
Population  2016 4.6 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 2.8 (1.6–4.2) 60 (35–91)
Mortality (HIV+TB only) 0.96 (0.6–1.4) 21 (13–30)
Incidence  (includes HIV+TB) 14 (9.2–20) 308 (199–440)
Incidence (HIV+TB only) 2.2 (1.4–3.2) 48 (31–70)
Incidence (MDR/RR-TB)** 0.43 (0.046–0.82) 9.4 (1–18)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females 0.77 (0.47–1.1) 4.4 (2.7–6.1) 5.2 (3.1–7.2)
Males 0.87 (0.53–1.2) 8.2 (5–11) 9 (5.5–13)
Total 1.6 (0.99–2.3) 13 (7.7–18) 14 (9.2–20)
TB case notifications, 2016  
Total cases notified 7 180
Total new and relapse 7 105
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 74%
          - % pulmonary 69%
          - % bacteriologically confirmed among pulmonary 63%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 50% (35–77)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.27 (0.14–0.42)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive 829 16%
          - on antiretroviral therapy 390 47%
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  160
(36–290)
Estimated % of TB cases with MDR/RR-TB 2.6% (0.1–5.1) 18% (0.1–36)  
% notified tested for rifampicin resistance 24% 100% 1 876
MDR/RR-TB cases tested for resistance to second-line drugs   0
Laboratory-confirmed cases MDR/RR-TB: 92, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 75, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2015 77% 6 147
Previously treated cases, excluding relapse, registered in 2015 65% 43
HIV-positive TB cases registered in 2015    
MDR/RR-TB cases started on second-line treatment in 2014   0
XDR-TB cases started on second-line treatment in 2014   0
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment 9%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
4.4% (4–4.8)
TB financing, 2017  
National TB budget (US$ millions) 1.7
Funding source: 24% domestic, 76% international, 0% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-12-16 Data: www.who.int/tb/data